EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa

Jessica Paken iD, Cyril Devadas Govender iD, Mershen Pillay, Merga Feyasa, Vikash Sewram

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0283639 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Jessica Paken und 4 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: Antineoplastic Agents, Uterine Cervical Neoplasms, Ototoxicity, Hearing Loss, Sensorineural. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African Medical Research Council, Oticon Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Concurrent chemoradiotherapy using weekly cisplatin remains standard of care for locally advanced cervical cancer in Sub-Saharan Africa. While cisplatin remains a popular cancer chemotherapeutic, it has an irreversible ototoxic effect on patients’ auditory system. However, there is a paucity of epidemiological information on its extent and severity during cervical cancer treatment. In a region with a high burden of cervical cancer, this has serious consequences for aural intervention and rehabilitation. Methods and findings Using a prospective cohort study design, 82 patients with incident cervical cancer, receiving weekly cisplatin chemotherapy (50 mg/m 2 body surface) at a tertiary level hospital in KwaZulu-Natal Province of South Africa, underwent audiological assessments at various intervals. We describe the temporal impact of cisplatin exposure on hearing loss, its combined effect with HIV-infection, and estimate ototoxicity incidence in this cohort. The median age was 52 years with Stages IIB (45%) and IIIB (35.4%) cancers being most common. Complaints of reduced hearing sensitivity increased significantly (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsUterine Cervical NeoplasmsOtotoxicityHearing Loss, SensorineuralHIV InfectionsFemaleHumansMiddle AgedCisplatinProspective StudiesSouth AfricaHearing Loss, BilateralAudiometry, Pure-Tone

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Discipline of Audiology, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Division of Epidemiology & Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Department of Global Health, Faculty of Medicine and Health Sciences, African Cancer Institute, Stellenbosch University, Cape Town, South Africa.

ORCID-Profile: Jessica Paken, Cyril Devadas Govender

Förderung

  • South African Medical Research Council
  • Oticon Fonden

Zitieren

APA

Paken, J., Govender, C. D., Pillay, M., Feyasa, M., & Sewram, V. (2023). Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa. PLOS ONE. https://doi.org/10.1371/journal.pone.0283639

Vancouver

Paken J, Govender CD, Pillay M, Feyasa M, Sewram V. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa. PLOS ONE. 2023. doi:10.1371/journal.pone.0283639

BibTeX
@article{Paken2023,
  author = {Paken, Jessica and Govender, Cyril Devadas and Pillay, Mershen and Feyasa, Merga and Sewram, Vikash},
  title = {Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0283639}
}
Kostenlos starten →